Cargando…

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauvin, Camille, Krishnan, Vimal, Kaci, Imane, Tran-Thanh, Danh, Bédard, Karine, Albadine, Roula, Leduc, Charles, Gaboury, Louis, Blais, Normand, Tehfe, Mustapha, Routy, Bertrand, Florescu, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924378/
https://www.ncbi.nlm.nih.gov/pubmed/33498159
http://dx.doi.org/10.3390/curroncol28010059
_version_ 1783659076850286592
author Gauvin, Camille
Krishnan, Vimal
Kaci, Imane
Tran-Thanh, Danh
Bédard, Karine
Albadine, Roula
Leduc, Charles
Gaboury, Louis
Blais, Normand
Tehfe, Mustapha
Routy, Bertrand
Florescu, Marie
author_facet Gauvin, Camille
Krishnan, Vimal
Kaci, Imane
Tran-Thanh, Danh
Bédard, Karine
Albadine, Roula
Leduc, Charles
Gaboury, Louis
Blais, Normand
Tehfe, Mustapha
Routy, Bertrand
Florescu, Marie
author_sort Gauvin, Camille
collection PubMed
description Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, p = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, p = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (p = 0.316), stage II (p = 0.024), and stage III (p = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting.
format Online
Article
Text
id pubmed-7924378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79243782021-03-03 Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC Gauvin, Camille Krishnan, Vimal Kaci, Imane Tran-Thanh, Danh Bédard, Karine Albadine, Roula Leduc, Charles Gaboury, Louis Blais, Normand Tehfe, Mustapha Routy, Bertrand Florescu, Marie Curr Oncol Article Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, p = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, p = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (p = 0.316), stage II (p = 0.024), and stage III (p = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting. MDPI 2021-01-20 /pmc/articles/PMC7924378/ /pubmed/33498159 http://dx.doi.org/10.3390/curroncol28010059 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gauvin, Camille
Krishnan, Vimal
Kaci, Imane
Tran-Thanh, Danh
Bédard, Karine
Albadine, Roula
Leduc, Charles
Gaboury, Louis
Blais, Normand
Tehfe, Mustapha
Routy, Bertrand
Florescu, Marie
Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title_full Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title_fullStr Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title_full_unstemmed Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title_short Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
title_sort survival impact of aggressive treatment and pd-l1 expression in oligometastatic nsclc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924378/
https://www.ncbi.nlm.nih.gov/pubmed/33498159
http://dx.doi.org/10.3390/curroncol28010059
work_keys_str_mv AT gauvincamille survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT krishnanvimal survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT kaciimane survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT tranthanhdanh survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT bedardkarine survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT albadineroula survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT leduccharles survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT gabourylouis survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT blaisnormand survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT tehfemustapha survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT routybertrand survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc
AT florescumarie survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc